Complement Inhibitors for C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis
Clinical Journal of the American Society of Nephrology · 18.11.2026
DOI: 10.2215/cjn.0000001254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 18.11.2026. Verfasst von Priyanka Khandelwal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Abstract (Originalsprache)
Background
C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are progressive kidney diseases driven by alternative complement pathway dysregulation. Although targeted complement inhibitors are promising, their comparative efficacy and safety remain uncertain. We evaluated these agents using Bayesian network meta-analysis.
Methods
We reviewed randomized controlled trials evaluating complement inhibitors in C3G and IC-MPGN (2015-2025). The primary outcome was relative change in proteinuria at 6-months. Secondary outcomes included change in estimated glomerular filtration rate (eGFR), C3G histologic index, and adverse events at 6-months. Treatment effects were estimated using Bayesian models and ranked using surface under the cumulative ranking curve (SUCRA). Sensitivity analyses included random-effects models and 52-week extension data. Certainty was assessed using GRADE-NMA. The protocol was registered in PROSPERO (CRD420251250384).
Results
Four trials, including 265 participants with trial-level mean ages 25-34 years (eligibility range, 12-80 years), evaluated pegcetacoplan, iptacopan, avacopan, and danicopan. Pegcetacoplan and iptacopan produced largest proteinuria reduction: pegcetacoplan -68.6% (95% credible interval [CrI], -83.2 to -54.0) and iptacopan -38.3% (95% CrI, -63.6 to -13.1) versus placebo (moderate certainty). In exploratory analyses, pegcetacoplan ranked highest (SUCRA 0.97), followed by iptacopan (0.66). Estimates for avacopan and danicopan were smaller, imprecise, and not statistically significant. Indirect comparisons were attenuated in sensitivity analyses, but hierarchy remained (low or very low certainty). Effects on eGFR were modest, without significant differences between active therapies. No therapy significantly improved C3G histologic index. Safety comparisons were limited by sparse events and short follow-up.
Conclusions
Pegcetacoplan and iptacopan were associated with prompt proteinuria reduction versus placebo in C3G/IC-MPGN, while short-term kidney function improvements are expectedly modest. Although pegcetacoplan appeared more effective in the fixed-effect indirect analysis, between-treatment differences do not establish definitive superiority given their model-sensitivity, between trial differences and unavailability of long-term kidney outcomes. Longer-term follow-up, real-world comparative effectiveness data, and biomarker-driven studies are needed.
Autor:innen und Institutionen
- Department of Pediatrics, Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Cell & Systems Biology, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Department of Medicine, Division of Nephrology, University of Toronto, Toronto Ontario, Canada.
- Department of Medicine, Division of Hematology, University of Toronto, Toronto Ontario, Canada.
- Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
ORCID-Profile: Priyanka Khandelwal, Anu Kaskinen, Arenn Jauhal, Christopher J Patriquin, Christoph Licht, Cal H Robinson
Zitieren
APA
Khandelwal, P., Kaskinen, A., Jauhal, A., Patriquin, C. J., Licht, C., & Robinson, C. H. (2026). Complement Inhibitors for C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000001254
Vancouver
Khandelwal P, Kaskinen A, Jauhal A, Patriquin CJ, Licht C, Robinson CH. Complement Inhibitors for C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000001254
BibTeX
@article{Khandelwal2026,
author = {Khandelwal, Priyanka and Kaskinen, Anu and Jauhal, Arenn and Patriquin, Christopher J and Licht, Christoph and Robinson, Cal H},
title = {Complement Inhibitors for C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
doi = {10.2215/cjn.0000001254}
}
EUVIMED